Skip to main content

Loading market data...

OCUL

Ocular Therapeutix, Inc.

NASDAQ • United states

$6.48

-$0.17

(-2.56%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Ocular Therapeutix, Inc. (OCUL)

Unavailable

Quotes may be delayed

$1.42B

Market Cap

2,487,782

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Ocular Therapeutix, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 15 CROSBY DRIVE, BEDFORD, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

17 Oct 2026

Ocular Therapeutix, Inc. reported A director or senior management change or compensation event

Ocular Therapeutix, Inc. filed an 8-K covering a director or senior management change or compensation event.

3 Aug 2026

Ocular Therapeutix, Inc. securities registration filing

Ocular Therapeutix, Inc. filed a registration or prospectus document concerning securities.

3 Aug 2026

Ocular Therapeutix, Inc. filed Form 10-Q

Ocular Therapeutix, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

3 Aug 2026

Ocular Therapeutix, Inc. reported Operating or financial results

Ocular Therapeutix, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

29 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Ocular Therapeutix, Inc..

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$598.64M

Total assets (USD)$671.32M

Total liabilities (USD)$151.28M

Shareholders' equity (USD)$520.04M

Long-term debt (USD)$18.00M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$13.48M	−$82.11M	−$78.76M	−$0.35	10-Q · 3 Aug 2026
Q1 2026	$10.79M	−$93.34M	−$88.61M	−$0.40	10-Q · 5 May 2026
Q4 2025	$13.25M	−$69.76M	−$64.65M	Unavailable	10-K · 5 Feb 2026
Q3 2025	$14.54M	−$68.70M	−$69.42M	−$0.38	10-Q · 4 Nov 2025
Q2 2025	$13.46M	−$67.64M	−$67.81M	−$0.39	10-Q · 5 Aug 2025
Q1 2025	$10.70M	−$63.92M	−$64.05M	−$0.38	10-Q · 5 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $24.13

272.4% upside potential

📈

Strong Buy

Unavailable

👍

Buy

9

⏸️

Hold

0

📉

Sell

0

9 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 22 Oct 2026, 01:50 UTC Targets range 14.00–31.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

8

Oct 2026

Anderman Todd

Chief Legal Officer

Open-market sale

$7.29 per share

11,984 shares

2

Oct 2026

Kaiser Peter

Chief Development Officer

Open-market sale

$7.05 per share

9,990 shares

2

Oct 2026

Heier Jeffrey S.

Chief Scientific Officer

Open-market sale

$7.05 per share

10,869 shares

31

Aug 2026

Notman Donald

Chief Operating Officer

Open-market sale

$10.24 per share

1,099 shares

25

Aug 2026

Dugel Pravin

Director, See Remarks

Gift

Unavailable per share

100,184 shares

24

Aug 2026

Kaiser Peter

Chief Development Officer

Open-market sale

$10.77 per share

3,035 shares

24

Aug 2026

Nayak Sanjay

Chief Strategy Officer

Open-market sale

$10.78 per share

1,897 shares

24

Aug 2026

Heier Jeffrey S.

Chief Scientific Officer

Open-market sale

$10.78 per share

3,296 shares

24

Aug 2026

Dugel Pravin

Director, See Remarks

Open-market sale

$10.77 per share

21,649 shares

Top Shareholders

Fmr Llc

32,844,043 shares

0.583% change

6/30/2026

Deep Track Capital, Lp

19,686,282 shares

0% change

6/30/2026

Blackrock, Inc.

19,376,555 shares

20.106% change

6/30/2026

Avoro Capital Advisors Llc

12,540,000 shares

1.827% change

6/30/2026

Summer Road Llc

12,208,296 shares

2.765% change

6/30/2026

Vanguard Group Inc

11,575,193 shares

26.322% change

12/31/2025

Venrock Adviser, Llc

10,346,926 shares

0% change

6/30/2026

Vanguard Capital Management Llc

8,832,595 shares

1.302% change

6/30/2026

Price T Rowe Associates Inc /Md/

7,623,533 shares

29.275% change

6/30/2026

Logos Global Management Lp

5,300,000 shares

37.662% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 22 Oct 2026, 01:50 UTC· 5 hours ago

Research coverage and investment tools

Ocular Therapeutix, Inc. (OCUL) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$6.48 on 21 Oct 2026. That is 5% of the way from its 52-week low of US$6.00 to its 52-week high of US$16.44. Its market capitalisation was US$1.42 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$13.48M	−$82.11M	−$78.76M	−$0.35	—	-609.3%	−$70.64M	10-Q · 3 Aug 2026 (opens in a new tab)
Q1 2026	$10.79M	−$93.34M	−$88.61M	−$0.40	—	-865.5%	−$70.66M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$13.25M	−$69.76M	−$64.65M	Unavailable	—	-526.5%	−$57.09M	10-K · 5 Feb 2026 (opens in a new tab)
Q3 2025	$14.54M	−$68.70M	−$69.42M	−$0.38	—	-472.3%	−$56.72M	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$13.46M	−$67.64M	−$67.81M	−$0.39	—	-502.6%	−$56.48M	10-Q · 5 Aug 2025 (opens in a new tab)
Q1 2025	$10.70M	−$63.92M	−$64.05M	−$0.38	—	-597.5%	−$46.60M	10-Q · 5 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/3/2026	−$0.35	−$0.40	+12.5%
Mar 2026	5/5/2026	−$0.41	−$0.32	-28.1%
Dec 2025	2/5/2026	−$0.29	−$0.33	+12.1%
Sep 2025	11/4/2025	−$0.37	−$0.39	+5.1%

Cash and equivalents: $598.64M
Total assets: $671.32M
Total liabilities: $151.28M
Shareholders' equity: $520.04M
Long-term debt: $18.00M

8-K · 17 Oct 2026 · Management change

Ocular Therapeutix, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Ocular Therapeutix, Inc. filed an 8-K covering a director or senior management change or compensation event.
S-8 · 3 Aug 2026

Ocular Therapeutix, Inc. securities registration filing (opens in a new tab)

Ocular Therapeutix, Inc. filed a registration or prospectus document concerning securities.
10-Q · 3 Aug 2026

Ocular Therapeutix, Inc. filed Form 10-Q (opens in a new tab)

Ocular Therapeutix, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 3 Aug 2026

Ocular Therapeutix, Inc. reported Operating or financial results (opens in a new tab)

Ocular Therapeutix, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G/A · 29 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Ocular Therapeutix, Inc..

Insider	Date	Transaction	Shares	Average price	Filing
Anderman Todd Chief Legal Officer	8 Oct 2026	Open-market sale (S)	−11,984	$7.29	Form 4 (opens in a new tab)
Kaiser Peter Chief Development Officer	2 Oct 2026	Open-market sale (S)	−9,990	$7.05	Form 4 (opens in a new tab)
Heier Jeffrey S. Chief Scientific Officer	2 Oct 2026	Open-market sale (S)	−10,869	$7.05	Form 4 (opens in a new tab)
Notman Donald Chief Operating Officer	31 Aug 2026	Open-market sale (S)	−1,099	$10.24	Form 4 (opens in a new tab)
Dugel Pravin Director, See Remarks	25 Aug 2026	Gift (G)	−100,184	—	Form 4 (opens in a new tab)
Kaiser Peter Chief Development Officer	24 Aug 2026	Open-market sale (S)	−3,035	$10.77	Form 4 (opens in a new tab)
Nayak Sanjay Chief Strategy Officer	24 Aug 2026	Open-market sale (S)	−1,897	$10.78	Form 4 (opens in a new tab)
Heier Jeffrey S. Chief Scientific Officer	24 Aug 2026	Open-market sale (S)	−3,296	$10.78	Form 4 (opens in a new tab)
Dugel Pravin Director, See Remarks	24 Aug 2026	Open-market sale (S)	−21,649	$10.77	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Fmr Llc	6/30/2026	32,844,043	0.583%
Deep Track Capital, Lp	6/30/2026	19,686,282	0%
Blackrock, Inc.	6/30/2026	19,376,555	20.106%
Avoro Capital Advisors Llc	6/30/2026	12,540,000	1.827%
Summer Road Llc	6/30/2026	12,208,296	2.765%
Vanguard Group Inc	12/31/2025	11,575,193	26.322%
Venrock Adviser, Llc	6/30/2026	10,346,926	0%
Vanguard Capital Management Llc	6/30/2026	8,832,595	1.302%
Price T Rowe Associates Inc /Md/	6/30/2026	7,623,533	29.275%
Logos Global Management Lp	6/30/2026	5,300,000	37.662%

Previous close: 6.65 USD
Day range: 6.38 – 6.75 USD
52-week range: 6.00 – 16.44 USD
Volume: 2,487,782
Market cap: $1.42B
Average volume: 3,261,246
EPS (FY 2025, diluted): −1.42 USD
Shares outstanding: 219.62M
Beta (5Y monthly): 1.21

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 11 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:15 UTC· 1 hour ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for OCUL yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.